Otsuka Holdings Co Ltd
TSE:4578

Watchlist Manager
Otsuka Holdings Co Ltd Logo
Otsuka Holdings Co Ltd
TSE:4578
Watchlist
Price: 8 594 JPY -0.07% Market Closed
Market Cap: 4.6T JPY
Have any thoughts about
Otsuka Holdings Co Ltd?
Write Note

Otsuka Holdings Co Ltd
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Otsuka Holdings Co Ltd
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Otsuka Holdings Co Ltd
TSE:4578
Net Issuance of Common Stock
-ÂĄ20B
CAGR 3-Years
-2 616%
CAGR 5-Years
-625%
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Net Issuance of Common Stock
-ÂĄ1.9B
CAGR 3-Years
10%
CAGR 5-Years
13%
CAGR 10-Years
20%
Daiichi Sankyo Co Ltd
TSE:4568
Net Issuance of Common Stock
-ÂĄ120.1B
CAGR 3-Years
-6%
CAGR 5-Years
-349%
CAGR 10-Years
-128%
S
Shionogi & Co Ltd
TSE:4507
Net Issuance of Common Stock
-ÂĄ55.7B
CAGR 3-Years
-4%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Chugai Pharmaceutical Co Ltd
TSE:4519
Net Issuance of Common Stock
ÂĄ212m
CAGR 3-Years
-12%
CAGR 5-Years
-18%
CAGR 10-Years
-15%
Astellas Pharma Inc
TSE:4503
Net Issuance of Common Stock
-ÂĄ7B
CAGR 3-Years
8%
CAGR 5-Years
35%
CAGR 10-Years
19%
No Stocks Found

Otsuka Holdings Co Ltd
Glance View

Market Cap
4.6T JPY
Industry
Pharmaceuticals

Otsuka Holdings Co. Ltd. began its journey in 1921 as a small chemicals company in Naruto, Japan. Its evolution from those humble beginnings to a global pharmaceutical giant is marked by its relentless commitment to innovation and expansion. Today, Otsuka operates as a holding company, orchestrating a diversified portfolio across pharmaceuticals, nutraceuticals, consumer products, and medical devices. It has cultivated a unique philosophy: a balance between large-scale operations and niche markets. The company’s pharmaceutical sector, its most significant revenue contributor, is driven largely by advancements in CNS (central nervous system) treatments and nephrology. The success of its flagship product, Abilify, a leading antipsychotic, underscores Otsuka’s ability to combine market demands with cutting-edge research to sustain growth and profitability. In parallel, Otsuka nurtures its nutraceuticals wing, embodied by its signature Pocari Sweat and SoyJoy brands. These products epitomize the company’s strategy of creating and expanding niche markets, offering health-oriented products that resonate with evolving consumer health trends. This diversification into consumer products and nutraceuticals not only complements its pharmaceutical endeavors but also mitigates risks by tapping into varied revenue streams. By focusing on health and wellness broadly, Otsuka Holdings strategically positions itself to navigate the complexities of the global healthcare market, ensuring a resilient business model. Through this multifaceted approach, Otsuka sustains its growth, reaffirming its legacy as a dynamic and globally influential company.

Intrinsic Value
9 450.44 JPY
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Otsuka Holdings Co Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
-20B JPY

Based on the financial report for Sep 30, 2024, Otsuka Holdings Co Ltd's Net Issuance of Common Stock amounts to -20B JPY.

What is Otsuka Holdings Co Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-625%

Over the last year, the Net Issuance of Common Stock growth was -2 003 800%. The average annual Net Issuance of Common Stock growth rates for Otsuka Holdings Co Ltd have been -2 616% over the past three years , -625% over the past five years .

Back to Top